2024-513393-22-00CompletedPhase 1
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Mar 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 4 Sept 2024
- Lead sponsor
- Merck Healthcare KGaA
- Diseases
- Lupus (SLE)
- EU CT number
- 2024-513393-22-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Management GmbH | Kiel | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.